
Research
-
Esophageal cancer breakthrough gets FDA approval
June 1, 2021Dr. Ronan Kelly authors study released in The New England Journal of Medicine on a global phase III clinical trial at 170 sites including Baylor University Medical Center in Dallas. The results of a study published in April in The New England Journal of Medicine (NEJM) found that the immunotherapy drug nivolumab (Opdivo®), if used […]Learn more Esophageal cancer breakthrough gets FDA approval -
The answer to successfully treating cancer lies within
March 1, 2021Baylor Scott & White Health fosters transformational immunology research that can lead to earlier diagnoses and novel immunotherapies through the new Texas Immuno-Oncology Biorepository (TIOB).Learn more The answer to successfully treating cancer lies within -
Drawing on the strength of the human body for innovative clinical trials
June 1, 2019Dr. Ronan Kelly, new chief of oncology at Baylor Scott & White Health – North Texas, is poised to help cancer patients benefit through greater access to novel research investigating next-generation immunotherapies.Learn more Drawing on the strength of the human body for innovative clinical trials